Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of sufentanil combined with remimazolam for suppression of tracheal intubation response
ChiCTR2300075949Phase 4Not yet recruiting
- Sponsor
- Nanchong City Central Hospital
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sufentanil and remimazolam in procedural pain (2 cohorts), sponsored by Nanchong City Central Hospital. Primary endpoint: Median effective dose (ED50) of sufentanil. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
sufentanilremimazolam
03
Conditions
procedural pain
Beyond the preview
Go deeper on ChiCTR2300075949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075949.